SCHEMBL5033495

SCHEMBL5033495

COc1ccc(-c2ccc(F)cc2)c2oc(NC(=O)c3ccc(C)nc3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADCY1 Q08828 5/20 0.42
KDM4E B2RXH2 2/20 0.42
CCR6 P51684 2/20 0.42
LMNA P02545 1/20 0.42
OPRK1 P41145 1/20 0.42
RECQL P46063 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40
ATM Q13315 1/20 0.40
ADORA2A P29274 3/20 0.40
ADORA1 P30542 3/20 0.40
ADORA2B P29275 2/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
WNT3A P56704 1/20 0.39
SCN9A Q15858 1/20 0.39
POLQ O75417 1/20 0.38
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037899 0.99 ADCY1 (0.44) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5037699 0.90 ADCY1 (0.51) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5033611 0.86 ADORA2A (0.47) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5036500 0.85 HTT (0.54) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5036203 0.82 ALDH1A1 (0.41) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5040819 0.81 ADORA2A (0.47) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5033620 0.79 ADORA2A (0.45) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5036593 0.79 ADORA2A (0.45) ADCY1KDM4ECCR6LMNAOPRK1
SCHEMBL5131523 0.79 HTT (0.43) KDM4ELMNAKMT2APOLBADORA2A
SCHEMBL5037775 0.78 ALDH1A1 (0.45) MEN1KMT2APOLBSCN9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP claimed
US-6992083-B2 deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide HOFFMAN-LA ROCHE INC. (US) 2006-01-31 US claimed
US-20040152702-A1 Benzoxazol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-05 US claimed
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP disclosed
US-6992083-B2 deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide HOFFMAN-LA ROCHE INC. (US) 2006-01-31 US disclosed
EP-1587799-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-26 EP disclosed
US-20040152702-A1 Benzoxazol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-05 US disclosed
WO-2004063177-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152702-A1 Benzoxazol derivatives P2RX3, P2RX2, P2RX1 ADCY1 420/4885KDM4E 2939/4885CCR6 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.